Research Keyword: glycosyltransferase

Mechanism Underlying Ganoderma lucidum Polysaccharide Biosynthesis Regulation by the β-1,3-Glucosyltransferase Gene gl20535

mycolabadmin

Researchers studied a gene called gl20535 in the medicinal mushroom Ganoderma lucidum that controls how the fungus makes beneficial polysaccharides. When they increased this gene’s activity, the mushroom produced significantly more polysaccharides with improved composition. The gene works by controlling sugar pathways and related enzyme production, and the mushroom compensates when this gene is reduced. These findings could help improve the production of medicinal mushroom products for food and health applications.

Read More »

Functional Approaches to Discover New Compounds via Enzymatic Modification: Predicted Data Mining Approach and Biotransformation-Guided Purification

mycolabadmin

Scientists are developing faster ways to discover new medicines from plants using two innovative methods. The first approach uses computer programs to predict which plant compounds can be chemically modified by enzymes to create new medicines with better properties. The second approach combines enzyme chemistry with traditional purification to directly isolate these modified compounds from plant extracts. These methods have successfully created new compounds with improved effectiveness against diseases like diabetes and cancer, often with much better solubility for medical use.

Read More »

Engineered biosynthesis and characterization of disaccharide-pimaricin

mycolabadmin

Scientists engineered a bacterium to produce a modified antibiotic called disaccharide-pimaricin that fights fungal infections with much better safety. This new compound dissolves better in water (107 times more soluble) and is much less toxic to human blood cells (12.6 times safer) compared to regular pimaricin, while still maintaining antifungal effectiveness. Through optimized fermentation processes, they achieved high production yields of 138 mg/L, making this a promising candidate for safer antifungal treatments.

Read More »

Cgm1 is a β-galactoside α-(1 → 4)-mannosyltransferase involved in the biosynthesis of capsular glucuronoxylomannogalactan in Cryptococcus neoformans

mycolabadmin

Researchers identified a new fungal enzyme called Cgm1 that helps the fungus Cryptococcus neoformans build its protective capsule, which allows it to evade the immune system. When this enzyme is disabled, the fungus becomes weak at body temperature and triggers a stronger immune response in infected mice. Since humans and plants don’t have this enzyme, it could be a promising target for developing new antifungal medications.

Read More »

Engineered biosynthesis and characterization of disaccharide-pimaricin

mycolabadmin

Scientists successfully created a genetically engineered bacterium that produces a safer version of an antifungal drug called pimaricin. The new version, called disaccharide-pimaricin, dissolves much better in water and causes significantly less damage to human blood cells, making it a much safer option for treating fungal infections. Although it’s slightly less effective at killing fungi, the improvement in safety and solubility makes it a promising candidate for treating eye infections and other fungal diseases.

Read More »
Scroll to Top